Phase 2 placebo-controlled study of evinacumab in severe hypertriglyceridemia at risk for acute pancreatitis

Phase 2, randomised, double-blind trial in hypertriglyceridemia comparing Evinacumab with Placebo (2 arms). Primary endpoints: Percent lowering of triglyceride levels from baseline at 12 weeks and Achievement of at least 40% triglyceride reduction from baseline placebo period. Started Feb 2018; status: completed.